Microbix Biosystems Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-5.72	-2.25	3.52	-0.04	1.79	3.23
Depreciation & Amortization	1.84	1.78	1.61	1.16	1.04	0.82
Stock-Based Compensation	0.63	0.65	0.71	0.74	0.65	0.38
Other Adjustments	0.61	0.49	0.27	-2.73	0.33	0.89
Changes in Other Operating Activities	-2.89	-0.76	-1.77	-0.22	-0.34	-3.22
Operating Cash Flow	-4.75	-0.08	4.35	-1.09	3.47	2.11
Operating Cash Flow Growth	-	-	-	-	64.48%	24494.21%
Capital Expenditures	-0.74	-0.8	-1.64	-1.02	-2.03	-1.24
Purchases of Intangible Assets	-	-	-0.27	-	-	-0.06
Investing Cash Flow	-0.74	-0.8	-1.91	-1.02	-2.03	-0.62
Long-Term Debt Issued	-	0.36	-	1.54	1.07	1.31
Long-Term Debt Repaid	-0.18	-1.21	-0.34	-0.11	-2.21	-0.35
Net Long-Term Debt Issued (Repaid)	-0.18	-0.85	-0.34	1.43	-1.14	0.96
Issuance of Common Stock	-	2.82	0.36	0.11	3.44	8.33
Repurchase of Common Stock	-0.84	-1.73	-0.93	-1.12	-	-
Net Common Stock Issued (Repurchased)	-0.84	1.09	-0.56	-1.01	3.44	8.33
Other Financing Activities	-0.25	-0.21	-0.18	-0.19	-0.25	-0.19
Financing Cash Flow	-0.92	0.03	-1.08	0.23	2.06	8.41
Net Cash Flow	-6.41	-0.85	1.36	-1.88	3.5	9.89
Free Cash Flow	-5.49	-0.88	2.71	-2.11	1.44	0.86
Free Cash Flow Growth	-	-	-	-	66.64%	-
FCF Margin	-37.07%	-4.72%	10.68%	-12.78%	7.55%	4.65%
Free Cash Flow Per Share	-0.04	-0.01	0.02	-0.02	0.01	0.01
Levered Free Cash Flow	-7.7	-2.87	1.38	1.31	-0.68	0.55
Unlevered Free Cash Flow	-9.11	-1.4	1.97	-5.89	1.22	1.2